Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s colitis (CD), are characterized by chronic and recurrent inflammation of the gastrointestinal tract. Anti-tumor necrosis factor (TNF) agents proved to be effective and safe in IBD. However, there are still concerns about the risk of malignancy and infections after long-term use of anti-TNF agents. There have been few data regarding the discontinuation of anti-TNF agents in IBD patients who achieved remission. This paper presents a study that focuses on the discontinuation of antiTNF agents and evaluates risk factors in predicting relapse of the disease. In the current issue, Song et al. conducted a retrospective, multicenter, uncontrolled study. They analyzed a total of 109 IBD patients (71 CD and 38 CD) treated with a first line anti-TNF agent (93 infliximab, 15 adalimumab, or one golimumab), and the median duration of the anti-TNF agent treatment was 12 months (range, 9.0 to 26.5 months). The cumulative relapse rates at 1, 2, 3, and 5 years for IBD patients were 17.4%, 32.9%, 46.7%, and 62.9%, respectively. The cumulative relapse rates for CD patients were 11.3%, 31.4%, 46.7%, and 62.5%, and those for UC patients, were 28.9%, 34.8%, 45.3%, and 60.9%, respectively. They suggested discontinuation owing to patients’ preference (vs clinician’s decision) and adalimumab group (vs infliximab group) as risk factors of disease relapse in CD patients. The non-mucosal healing group (vs mucosal healing group) in UC was suggested to be a high-risk group of disease relapse. Despite its retrospective design, lack of therapeutic drug monitoring, and inadequate measurement of endoscopic parameters, this study appears to be meaningful because it is the first report about the discontinuation of antiTNF agents in the real-life clinical practice in Korea. Recently, Kobayashi et al. performed a first multicenter, open-labeled randomized controlled trial (RCT) in patients with UC treated with first line infliximab, and the median duration of infliximab treatment in discontinued infliximab group was 164.6 weeks. The median disease duration of discontinued infliximab group was 5.4 years. The cumulative relapse rates at 8, 16, 24, 32, 40, and 48 weeks for UC patients were 6.5%, 23.9%, 26.1%, 32.6%, 34.8%, and 45.7%, respectively. The relapse rates of UC in the study by Song et al. was relatively lower, approximately 20%, compared to this RCT. The study population of in the study by Song et al. had a higher rate of ulcerative proctitis compared to the study by Kobayashi et al. (23.7% vs 2.0%). Also, the maintenance duration of anti-TNF in the study by Song et al. was relatively shorter compared to the study by Kobayashi et al. (48 weeks vs 164.6 weeks). The reasons for discontinuation of anti-TNF agents were various in real-life settings, which includes not only clinician’s decision but also patient’s preference. The relatively shorter maintenance duration of anti-TNF may indicate a lower inflammatory disease burden, which might have affected the outcomes. In terms of CD, Louis et al. performed a prospective, multicenter, uncontrolled trial with 125 patients treated with first line infliximab, and the median duration of inf-